Viyash Scientific reported a record revenue of ₹3,420.3 crore and a significant jump in PAT to ₹224.6 crore for FY26. This follows its successful amalgamation and indicates strong post-merger synergy realization.
Viyash Scientific Reports Record FY26 Financials Post-Amalgamation
Consolidated Revenue: ₹3,420.3 crore Consolidated PAT: ₹224.6 crore Reader Takeaway: Strong revenue and profit growth driven by merger synergies; focus shifts to scaling new capabilities. ## What just happened Viyash Scientific Ltd has announced its financial results for the fiscal year 2025-26 (FY26), reporting a consolidated revenue of ₹3,420.3 crore and a Profit After Tax (PAT) of ₹224.6 crore. This marks a significant increase from FY25, where revenue stood at ₹3,006.8 crore and PAT was ₹15.77 crore. ## Why this matters The strong financial performance highlights the successful integration and synergy realization following the amalgamation of Viyash Life Sciences and SeQuent Scientific, effective December 16, 2025. The company's EBITDA also saw a substantial jump of 59.6% to ₹702.5 crore, with margins improving to over 20%. This indicates enhanced operational efficiency and profitability for the newly formed Viyash Scientific Limited. ## The backstory Viyash Scientific Limited was established as an integrated entity combining capabilities in human health, animal health, and API/CDMO following the successful completion of the Scheme of Amalgamation. The previous fiscal year, FY25, was a period of transition and restructuring. ## What changes now The company's financial flexibility has improved, with its Net Debt to EBITDA ratio decreasing to 0.24x in FY26 from 1.03x in FY25. Furthermore, its long-term bank facilities rating was upgraded to IND AA- (Stable) by India Ratings. This stronger balance sheet and improved credit rating provide a solid foundation for future growth initiatives. ## Risks to watch While the company celebrates strong results, investors will be keen to monitor the scaling of its companion animal infrastructure and the commercial success of its Contract Development and Manufacturing Organization (CDMO) capabilities, which management has identified as key growth segments. ## Peer comparison (No specific peer data available in the filing) ## Context metrics (time-bound) * Consolidated Revenue FY26: ₹3,420.3 crore (vs. ₹3,006.8 crore FY25) * Consolidated EBITDA FY26: ₹702.5 crore (vs. ₹440.0 crore FY25) * Consolidated PAT FY26: ₹224.6 crore (vs. ₹15.77 crore FY25) * Net Debt/EBITDA FY26: 0.24x (vs. 1.03x FY25) ## What to track next Investors should track the company's progress in expanding its companion animal business and the successful commercialization of its CDMO services in the upcoming fiscal year, FY27.
